1. Home
  2. PMM vs ACIU Comparison

PMM vs ACIU Comparison

Compare PMM & ACIU Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • PMM
  • ACIU
  • Stock Information
  • Founded
  • PMM 1989
  • ACIU 2003
  • Country
  • PMM United States
  • ACIU Switzerland
  • Employees
  • PMM N/A
  • ACIU N/A
  • Industry
  • PMM Investment Managers
  • ACIU Biotechnology: Pharmaceutical Preparations
  • Sector
  • PMM Finance
  • ACIU Health Care
  • Exchange
  • PMM Nasdaq
  • ACIU Nasdaq
  • Market Cap
  • PMM 296.6M
  • ACIU 332.4M
  • IPO Year
  • PMM N/A
  • ACIU 2016
  • Fundamental
  • Price
  • PMM $6.36
  • ACIU $3.22
  • Analyst Decision
  • PMM
  • ACIU Strong Buy
  • Analyst Count
  • PMM 0
  • ACIU 2
  • Target Price
  • PMM N/A
  • ACIU $12.00
  • AVG Volume (30 Days)
  • PMM 118.3K
  • ACIU 134.3K
  • Earning Date
  • PMM 01-01-0001
  • ACIU 11-05-2024
  • Dividend Yield
  • PMM 4.68%
  • ACIU N/A
  • EPS Growth
  • PMM N/A
  • ACIU N/A
  • EPS
  • PMM 0.23
  • ACIU N/A
  • Revenue
  • PMM N/A
  • ACIU $48,505,404.00
  • Revenue This Year
  • PMM N/A
  • ACIU N/A
  • Revenue Next Year
  • PMM N/A
  • ACIU $938.44
  • P/E Ratio
  • PMM $26.52
  • ACIU N/A
  • Revenue Growth
  • PMM N/A
  • ACIU 4097200.00
  • 52 Week Low
  • PMM $5.00
  • ACIU $2.25
  • 52 Week High
  • PMM $6.42
  • ACIU $5.14
  • Technical
  • Relative Strength Index (RSI)
  • PMM 62.73
  • ACIU 52.46
  • Support Level
  • PMM $6.15
  • ACIU $3.29
  • Resistance Level
  • PMM $6.46
  • ACIU $3.48
  • Average True Range (ATR)
  • PMM 0.07
  • ACIU 0.21
  • MACD
  • PMM 0.03
  • ACIU 0.02
  • Stochastic Oscillator
  • PMM 84.52
  • ACIU 36.36

About PMM Putnam Managed Municipal Income Trust

Putnam Managed Municipal Income Trust is a closed-end management investment company. Its investment objective is to seek a high level of current income exempt from federal income tax by investing in a diversified portfolio of tax-exempt municipal securities. The Fund invests in various sectors such as healthcare, retirement community, private higher education, housing-backed, essential service utilities, and state-backed bonds.

About ACIU AC Immune SA

AC Immune SA is a clinical-stage biopharmaceutical company that focuses on neurodegenerative diseases. The company uses its proprietary technology platforms to discover, design, and develop novel proprietary small molecules, antibodies, and vaccines for the prevention, diagnosis, and treatment of neurodegenerative diseases associated with protein misfolding. The Company has one segment. The Company currently focuses most of its resources on discovering and developing therapeutic and diagnostic products targeting misfolded proteins. The company's pipeline consists of ACI-24.060, Crenezumab, ACI-35.030, Semorinemab, ACI-7104.056, and others.

Share on Social Networks: